The Billion-Dollar Pivot: Why Big Pharma is Abandoning ctDNA for Viable CTC Isolation
The global oncology market is facing an aggressive reallocation of capital. For nearly a decade, liquid biopsy investments heavily favored standard circulating tumor DNA (ctDNA test) infrastructures. However, as next-generation targeted modalities like ADCs and PROTACs dominate pipelines in 2026, the structural limits of sequencing fragmented, dead genetic materials have exposed severe clinical gaps. Leading … Read more